瑞康医药
(002589)
| 流通市值：41.65亿 | | | 总市值：45.89亿 |
| 流通股本：13.66亿 | | | 总股本：15.05亿 |
| 利润表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 营业总收入 | 3,414,747,352.56 | 1,707,482,764.51 | 7,295,858,461.63 | 5,406,533,649.77 |
| 营业总成本 | 3,418,218,716.66 | 1,692,322,269.95 | 7,353,302,934.53 | 5,455,252,955.23 |
| 其他经营收益 | | | | |
| 营业利润 | 38,703,943.21 | 16,451,078.9 | 16,851,413.47 | 16,527,171.53 |
| 利润总额 | 38,061,252.83 | 16,316,658.19 | 2,687,248.69 | 4,545,017.87 |
| 净利润 | 30,336,863.47 | 15,619,562.1 | 43,902,130.25 | 27,004,113.8 |
| 每股收益 | | | | |
| 其他综合收益 | - | - | - | - |
| 综合收益总额 | 30,336,863.47 | 15,619,562.1 | 43,902,130.25 | 27,004,113.8 |
| 资产负债表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 流动资产: | | | | |
| 流动资产合计 | 11,022,521,611.83 | 10,604,910,222.91 | 9,453,107,172.42 | 10,443,029,336.14 |
| 非流动资产: | | | | |
| 非流动资产合计 | 4,926,646,944.02 | 4,941,621,251.61 | 4,916,737,181.83 | 4,885,924,680.64 |
| 资产总计 | 15,949,168,555.85 | 15,546,531,474.52 | 14,369,844,354.25 | 15,328,954,016.78 |
| 流动负债: | | | | |
| 流动负债合计 | 10,234,405,337.84 | 9,656,108,240.61 | 8,661,925,568.6 | 9,398,039,209.22 |
| 非流动负债: | | | | |
| 非流动负债合计 | 263,907,105.73 | 445,798,507.95 | 285,177,120.38 | 476,734,746.18 |
| 负债合计 | 10,498,312,443.57 | 10,101,906,748.56 | 8,947,102,688.98 | 9,874,773,955.4 |
| 所有者权益(或股东权益): | | | | |
| 归属于母公司股东权益合计 | 5,308,602,738.38 | 5,316,269,316.03 | 5,299,633,603.76 | 5,348,973,670.93 |
| 股东权益合计 | 5,450,856,112.28 | 5,444,624,725.96 | 5,422,741,665.27 | 5,454,180,061.38 |
| 负债和股东权益合计 | 15,949,168,555.85 | 15,546,531,474.52 | 14,369,844,354.25 | 15,328,954,016.78 |
| 现金流量表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 经营活动产生的现金流量: | | | | |
| 经营活动现金流入小计 | 3,900,031,999.8 | 1,970,317,059.56 | 8,206,117,454.8 | 6,192,029,131.79 |
| 经营活动现金流出小计 | 3,851,314,086.48 | 1,968,100,134.58 | 8,192,357,927.72 | 6,151,452,949.1 |
| 经营活动产生的现金流量净额 | 48,717,913.32 | 2,216,924.98 | 13,759,527.08 | 40,576,182.69 |
| 投资活动产生的现金流量: | | | | |
| 投资活动现金流入小计 | 904,094,775.39 | 367,281,071.37 | 1,698,391,040.58 | 372,374,297.38 |
| 投资活动现金流出小计 | 973,073,243.49 | 461,145,294 | 1,750,192,807.31 | 499,479,265.73 |
| 投资活动产生的现金流量净额 | -68,978,468.1 | -93,864,222.63 | -51,801,766.73 | -127,104,968.35 |
| 筹资活动产生的现金流量: | | | | |
| 筹资活动现金流入小计 | 10,269,832,637.08 | 4,323,188,181.52 | 20,847,997,499.72 | 13,337,365,337.14 |
| 筹资活动现金流出小计 | 10,062,862,970.33 | 4,030,409,668.07 | 20,782,039,199.17 | 13,450,865,255.42 |
| 筹资活动产生的现金流量净额 | 206,969,666.75 | 292,778,513.45 | 65,958,300.55 | -113,499,918.28 |
| 汇率变动对现金及现金等价物的影响 | - | - | 0 | - |
| 现金及现金等价物净增加额 | 186,709,111.97 | 201,131,215.8 | 27,916,060.9 | -200,028,703.94 |
| 期末现金及现金等价物余额 | 904,948,098.94 | 919,370,202.77 | 718,238,986.97 | 490,294,222.13 |
| 补充资料: | | | | |
| 现金及现金等价物的净增加额 | 186,709,111.97 | - | 27,916,060.9 | - |